BI
IMVT icon

BVF Inc’s Immunovant IMVT Stock Holding History

BVF Inc’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-300,000
Closed -$12.6M – 65
2023
Q4 		$12.6M Hold
300,000
– – 0.32% 46
2023
Q3 		$11.5M Buy
+300,000
New +$6.78M 0.31% 45
2023
Q2 		– Sell
-2,561,000
Closed -$39.7M – 71
2023
Q1 		$39.7M Hold
2,561,000
– – 1.45% 22
2022
Q4 		$45.5M Buy
+2,561,000
New +$32.2M 1.92% 20
2021
Q3 		– Sell
-1,273,516
Closed -$13.5M – 78
2021
Q2 		$13.5M Buy
1,273,516
+129,500
+11% +$1.81M 0.5% 47
2021
Q1 		$18.4M Buy
1,144,016
+629,646
+122% +$16.6M 0.69% 35
2020
Q4 		$23.8M Sell
514,370
-684,057
-57% -$31.6M 0.93% 30
2020
Q3 		$42.2M Buy
1,198,427
+109,948
+10% +$3.31M 2.3% 16
2020
Q2 		$26.5M Buy
1,088,479
+88,483
+9% +$1.9M 1.63% 23
2020
Q1 		$15.6M Hold
999,996
– – 1.45% 22
2019
Q4 		$15.8M Buy
+999,996
New +$11.2M 1.2% 20

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BVF Inc's IMVT Position: Q1 2024 in Review

BVF Inc sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 300,000 shares — an estimated $12.6M sold.

BVF Inc first reported a position in IMVT in Q4 2019 and held it in 11 quarters. The position peaked at $45.5M in Q4 2022. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • BVF Inc reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • BVF Inc sold 300,000 Immunovant shares in Q1 2024, an estimated $12.6M.
  • BVF Inc first reported a position in Immunovant in Q4 2019 and held it in 11 quarters.
  • BVF Inc's Immunovant position peaked at $45.5M in Q4 2022.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.